Moleculin Biotech - MBRX

09/08/2026

This Leukemia Awareness Month, we recognize those living with leukemia and the families, caregivers and healthcare professionals alongside them.

At Moleculin, we remain focused on advancing research in acute myeloid leukemia and pursuing new possibilities for patients.

09/02/2026

Blood Cancer Awareness Month shines a light on the need for continued progress for people facing diseases like acute myeloid leukemia.

At Moleculin, that need drives our work to advance new therapeutic approaches for patients with limited treatment options.

08/27/2026

In Moleculin's new "Why Now" webcast, Moleculin CEO Walter Klemp highlights Annamycin's differentiated clinical profile, continued enrollment progress, expanding commercial opportunity, and the upcoming 90-patient interim analysis as a key value-driving catalyst supporting the Company's path toward potential registration. Watch here: https://bit.ly/4qEWH2d

08/27/2026

Moleculin today announced that it participated in the Virtual Investor “Why Now” on-demand conference. During the the presentation, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, highlighted the Company's clinical progress and long-term opportunity, discussing encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for the treatment of relapsed or refractory AML. Watch now: https://bit.ly/4qEWH2d

08/21/2026

The next Moleculin update is just an email away.

Subscribe to receive company announcements, clinical progress and investor news as soon as they're released.

Sign up here: https://bit.ly/3vdevGH

08/14/2026

Moleculin’s pivotal MIRACLE trial is advancing toward its planned 90-patient enrollment milestone in September 2026, with the unblinded efficacy readout in December 2026 to February 2027. Part B initiation expected in the first half of 2027 following optimal dose selection. Read more: https://bit.ly/3TXlgez

08/14/2026

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML. For more recent highlights and a clinical development update, visit: https://bit.ly/3TXlgez

08/14/2026

Moleculin today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress in its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML). Read more: https://bit.ly/3TXlgez

08/13/2026

The majority of patients with relapsed or refractory AML remain underserved by currently approved therapies. Better treatment options are urgently needed.

That's the challenge Moleculin Biotech is working to address.

08/06/2026

Learn more about Moleculin's latest Virtual Investor "What This Means" segment, where CEO Walter Klemp discusses positive preliminary MIRACLE trial results and what they could mean for Annamycin.

Read more: https://bit.ly/4fotpAX

Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment. ...